# US 2021/0069064 A1 · A manufacturing method of an herbal medicinal tablet formulation for treating obesity which can be prescribed based on sasang constitutional medicine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0069064 A1
- Document ID: US20210069064A1
- Status: Published application
- Kind: A1
- Application number: 16/957,432
- Filed: 2018-12-20
- Published: 2021-03-11
- Earliest claimed: 2017-12-29
- Assignees: Nubebe Co., Ltd.; Human Herb Co., Ltd.
- Applicants: Nubebe Co., Ltd.; Human Herb Co., Ltd.
- Inventors: Young Woo LIM; Ji Myeong OK; Woon Ho LEE; Young Bin KIM
- Web page: https://patentgrep.com/patent/US20210069064A1

## CPC

- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61J 3/06: into the form of pills, lozenges or dragees
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 9/28: Dragees; Coated pills or tablets {, e.g. with film or compression coating (A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209)}
- A61K 33/04: Sulfur, selenium or tellurium; Compounds thereof
- A61K 36/076: Poria
- A61K 36/17: Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
- A61K 36/185: Magnoliopsida (dicotyledons)
- A61K 36/258: Panax (ginseng)
- A61K 36/284: Atractylodes
- A61K 36/31: Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K 36/346: Platycodon
- A61K 36/481: Astragalus (milkvetch)
- A61K 36/488: Pueraria (kudzu)
- A61K 36/49: Fagaceae (Beech family), e.g. oak or chestnut
- A61K 36/534: Mentha (mint)
- A61K 36/538: Schizonepeta
- A61K 36/54: Lauraceae (Laurel family), e.g. cinnamon or sassafras
- A61K 36/575: Magnolia
- A61K 36/62: Nymphaeaceae (Water-lily family)
- A61K 36/64: Orobanchaceae (Broom-rape family)
- A61K 36/65: Paeoniaceae (Peony family), e.g. Chinese peony
- A61K 36/708: Rheum (rhubarb)
- A61K 36/725: Ziziphus, e.g. jujube
- A61K 36/734: Crataegus (hawthorn)
- A61K 36/736: Prunus, e.g. plum, cherry, peach, apricot or almond
- A61K 36/744: Gardenia
- A61K 36/752: Citrus, e.g. lime, orange or lemon
- A61K 36/882: Acoraceae (Calamus family), e.g. sweetflag or Acorus calamus
- A61K 36/884: Alismataceae (Water-plantain family)
- A61K 36/8945: Dioscorea, e.g. yam, Chinese yam or water yam
- A61K 36/8994: Coix (Job's tears)
- A61K 36/9068: Zingiber, e.g. garden ginger
- A61K 47/02: Inorganic compounds
- A61K 47/46: Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
- A61P 3/04: Anorexiants; Antiobesity agents
- A61K 2236/00: Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An embodiment of the present invention provides a manufacturing method of an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine, comprises manufacturing a concentrated and quantified ephedra powder agent so that an ephedrine content of ephedra, which differs from 0.5-2.5% depending on a producing district and collecting period, is 3.0-4.0%, determining a weight according to each constitution of Sasang constitutional medicine of the concentrated and quantified ephedra powder agent of which the ephedrine content is 3.0-4.0%, and manufacturing a side-effect-preventing powder agent for each constitution to prevent and suppress side effects according to constitution of Sasang constitutional medicine with respect to the weight of the ephedra powder agent, preparing the ephedra powder agent and the side-effect-preventing powder agent while varying a weight ratio therebetween in consideration of weight, obesity, constitution of Sasang constitutional medicine, and side effects while mixing the ephedra powder agent and the side-effect-preventing powder agent; tableting a mixture of the prepared ephedra powder agent and side-effect-preventing powder agent; coating the tableted ones after tableting; and after the coating, while sorting out defective ones from coated ones and packaging, displaying a label including information prepared according to weight, obesity, constitution of Sasang constitutional medicine, and side effects.

## Claims

### Claim 1

A manufacturing method of an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine, comprising:
manufacturing a concentrated and quantified ephedra powder agent so that an ephedrine content of ephedra, which differs from 0.5-2.5% depending on a producing district and collecting period, is 3.0-4.0%;
determining a weight according to each constitution of Sasang constitutional medicine of the concentrated and quantified ephedra powder agent of which the ephedrine content is 3.0-4.0%, and manufacturing a side-effect-preventing powder agent for each constitution to prevent and suppress side effects according to constitution of Sasang constitutional medicine with respect to the weight of the ephedra powder agent;
preparing the ephedra powder agent and the side-effect-preventing powder agent while varying a weight ratio therebetween in consideration of weight, obesity, constitution of Sasang constitutional medicine, and side effects while mixing the ephedra powder agent and the side-effect-preventing powder agent;
tableting a mixture of the prepared ephedra powder agent and side-effect-preventing powder agent;
coating the tableted ones after tableting; and
after the coating, while sorting out defective ones from coated ones and packaging, displaying a label including information prepared according to weight, obesity, constitution of Sasang constitutional medicine, and side effects.

### Claim 2 (depends on 1)

The manufacturing method of an herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine of claim 1, wherein
when the ephedrine content is constant at 3-4%, a weight of the ephedra powder agent is about 360 g for Taeyangin, about 297 g for Soeumin, and about 360 g for Soyangin, and a weight ratio of the side-effect-preventing powder agent for each constitution with respect to a weight of the ephedra powder agent is about 8-10:1 for Taeyangin, about 9-11:1 for Soeumin, and about 8-10:1 for Soyangin.

### Claim 3 (depends on 1)

The manufacturing method of the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine of claim 1, wherein
the ephedrine content is, based on one day, 60 to 90 mg for normal weight, overweight, and initial obesity; 80 to 120 mg for overweight and obesity, 90 to 120 mg for moderate and extreme obesity, and 130 to 140 mg for tolerance, moderate, and extreme obesity.

### Claim 4 (depends on 1)

The manufacturing method of the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine of claim 1, wherein
the manufacturing of the concentrated and quantified ephedra powder agent so that the ephedrine content is 3.0-4.0% includes primarily quantifying the ephedrine content to be 7 to 8 Brix through Brix measurement every 2 hours in a hydraulic decocting process; and
secondarily quantifying the ephedrine content to be 30 to 35 Brix through Brix measurement every 2 hours in a low temperature vacuum concentration process.

### Claim 5 (depends on 4)

The manufacturing method of the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine of claim 4, further comprising
filtering a foreign matter through a sieve with a 45 mesh scale after the secondarily quantifying.

### Claim 6 (depends on 4)

The manufacturing method of the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine of claim 4, wherein
the manufacturing of the concentrated and quantified ephedra powder agent so that the ephedrine content is 3.0-4.0% further includes lyophilizing the ephedra powder agent of 30 to 35 Brix that is secondarily quantified, and
in the lyophilizing, a freezing condition is 8 hours at a temperature of −30 to −40° C., and a drying condition is at least 60 hours at a temperature of 30 to 40° C.

### Claim 7 (depends on 6)

The manufacturing method of the herbal medicinal tablet formulation for treating obesity which can be prescribed based on Sasang constitutional medicine of claim 6, further comprising
measuring and labeling an ephedrine content of the lyophilized ephedra powder agent, and airtightly packing the lyophilized ephedra powder agent and side-effect-preventing powder agent for each constitution.
